Evidence map›Paper›PMID 37726862›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2023

Pretreatment

Guang Ma, Shuhui You, Yizhao Xie, Bingxin Gu, Cheng Liu, Xichun Hu, Shaoli Song, Biyun Wang, Zhongyi Yang

Open access · goldAbstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 citations in OpenAlex.

  1. Prognostic value of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Guang Ma *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shuhui You *Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Yizhao XieDepartment of Medical Oncology, Zhongshan Hospital Fudan University, Shanghai, China.
Bingxin GuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Cheng LiuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Xichun HuDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Biyun WangDepartment of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. wangbiyun0107@hotmail.com.
Zhongyi YangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. yangzhongyi21@163.com.
Fudan University Shanghai Cancer Center · CNFudan University · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

National Natural Science Foundation of China 81901778Shanghai Committee of Science and Technology Fund 22DZ2204500Shanghai Municipal Health Commission 202040269Shanghai Sailing Program 20YF1408500
6 · The paper itself

Abstract

objectiveIntra-tumoral heterogeneity of

methodsThirty-two patients with MHBC who underwent

resultsThe survival analysis showed that HI

conclusion

Indexed as

Breast NeoplasmsFluorodeoxyglucose F18Antibodies, Monoclonal, HumanizedFemaleHumansPositron Emission Tomography Computed TomographyRetrospective StudiesTrastuzumabTreatment OutcomeAntibodies, Monoclonal, HumanizedFluorodeoxyglucose F18pertuzumabTrastuzumabDual target therapyHeterogeneity of 18F-FDG uptakeMetastatic HER2 positive breast cancerPrognosis

Identifiers

PMID37726862
PMCPMC10510219
OpenAlexW4386861458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.